Anticardiolipin and anti-β₂GPI antibodies in a large series of European patients with systemic lupus erythematosus

References

• Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, et al. Anticardiolipin antibodies. Detection by radioimmunoassay and association with throm-bosis in SLE. Lancet 1983;ii:1211–4.
   Google Scholar
• Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Antiphospholipid antibodies: isotype distribution and phos-pholipid specificity. Ann Rheum Dis 1987;46:1–6.
   PubMed Web of Science ®Google Scholar
• Hughes GRV. The antiphospholipid syndrome. Lupus 1996;5:345–6.
   PubMed Web of Science ®Google Scholar
• McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: beta2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120–4.
   PubMed Web of Science ®Google Scholar
• Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544–7.
   Google Scholar
• Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(sand differential diagnosis of auto-immune disease (letter). Lancet 1990;336:177–8.
   Google Scholar
• Hunt J, Krilis S. The fifth domain of beta2-glycoprotein I contains a phospholipid binding site (Cys 281-Cys 288) and a region recognized by anticardiolipin antibodies. J Immunol 1994;152:653–9.
   PubMed Web of Science ®Google Scholar
• Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992;148:3885–91.
   PubMed Web of Science ®Google Scholar
• Martinuzzo ME, Forastiero RR, Carreras LO. Anti-132-glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995;89: 397–402.
   Google Scholar
• Balestrieri G, Tincani A, Spatola L, Allegri F, Prati E, Cattaneo R, et al. Anti-beta2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995;4:122–30.
   PubMed Web of Science ®Google Scholar
• Navarro M, Cervera R, Teixidô M, Reverter JC, Font J, Uppez-Soto A, et al. Antibodies to endothelial cells and to b2-glycoprotein I in the antiphospholipid syndrome: prevalence and isotype distribution. Br J Rheumatol 1996;35: 523–8.
   Google Scholar
• Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, et al. Antibodies to b2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466–74.
   PubMed Web of Science ®Google Scholar
• Roubey RAS, Maldonado MA, Byrd SN. Comparison of an enzyme-linked immunosorbent assay for antibodies to b2- glycoprotein I and a conventional anticardiolipin immuno-assay. Arthritis Rheum 1996;39: 1606–7.
   Google Scholar
• Piette JC. 1996 diagnostic and classification criteria for the antiphospholipid/cofactors syndrome: a "mission impossible"? Lupus 1996;5:354–63.
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Cabral AR. The concept and classifica-tion of antiphospholipid/cofactor syndrome. Lupus 1996;5: 364–7.
   Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982;25:1271–7.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1.000 patients. Medicine (Baltimore) 1993;72:113–24.
   PubMed Web of Science ®Google Scholar
• Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987;68: 215–22.
   PubMed Web of Science ®Google Scholar
• Polz E, Wurm H, Kostner GM. Investigation on I32GPI in rat: isolation from serum and demonstration in lipoprotein density fraction. J Biochem 1980;11: 265–70.
   Google Scholar
• La Rosa L, Meroni PL, Tincani A, Balestrieri G, Faden D, Lojacono A, et al. Beta 2 glycoprotein I and placental anticoagulant protein 1 in placentae from patients with antiphospholipid syndrome. J Rheumatol 1994;21:1684–93.
   PubMed Web of Science ®Google Scholar
• Love PE, Santoro SA. Antiphospholipid antibodies: anti-cardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Ann Intern Med 1990;112:682–98.
   PubMed Web of Science ®Google Scholar
• Roubey RAS, Maldonado MA, Byrd SN, Winfield JB. Elisa for autoantibodies to Beta2-glycoprotein I: comparison with a standard "anticardiolipin" assay. Arthritis Rheum 1994;37: S296 (abstract).
   Google Scholar
• Balestrieri G, Tincani A, Spatola L, et al. Anti-beta-2-glycoprotein I antibodies: a marker of antiphospholipid syndrome? Lupus 1995;4:122–30.
   PubMed Web of Science ®Google Scholar
• Alarcon-Segovia D, Cabral AR. Autoantibodies in systemic lupus erythematosus. Curr Opin Rheumatol 1996;8:403–7.
   PubMedGoogle Scholar
• McNally T, Purdy G, Mackie IJ, Machin SJ, Isenberg DA. The use of an anti-beta-2-glycoprotein I assay for discrimina-tion between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995;91: 471–3.
   Google Scholar
• Faden D, Tincani A, Tanzi P, et al. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-beta 2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997;73: 37–42.
   Google Scholar
• Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta2-glycoprotein I structure altered by interacting with an oygen modified solid phase surface. J Exp Med 1994;179: 457–62.
   Google Scholar
• Roubey RA, Eisenberg RA, Harper MF, Winfield JB. "Anticardiolipin" autoantibodies recognize beta 2-glycopro-tein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995;154:954–60.
   Google Scholar
• Tincani A, Spatola L, Prati E, et al. The anti-beta-2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes locate on native beta-2- glycoprotein I and preserved during species' evolution. J Immunol 1996;157:5732–8.
   PubMed Web of Science ®Google Scholar
• Sheng Y, Kandiah DA, Krilis SA. Anti-beta 2-glycoprotein I autoantibodies from patients with the "antiphospholipid" syndrome bind to beta 2-glycoprotein I with low affinity: dimerization of beta 2-glycoprotein I induces a significant increase in anti-beta 2-glycoprotein I antibody affinity. J Immunol 1998;161: 2038–43.
   Google Scholar
• Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996;39:1444–54.
   PubMed Web of Science ®Google Scholar
• Viard J-P, Amoura Z, Bach J-F. Association of anti-I32-glycoprotein I antibodies with lupus-type circulating anti-coagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93: 181–6.
   Google Scholar
• Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical mani-festations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-132-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22: 1899–906.
   Google Scholar
• Day TM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC. Autoantobody to beta2-glicoprotein I in systemic lupus erythematosus and primary antiphospholipid antobody syndrome: clinical correlation in comparison with other antiphospholipid antibody tests. J Rheumatol 1998;25: 667–74.
   PubMed Web of Science ®Google Scholar
• Horbach DA, van Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916–24.
   Google Scholar
• Sammaritano L, Ng S, Sobel R, Lo SK, Simantov R, Furie R, et al. Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis. Arhtritis Rheum 1997;40:1998 — 2006.
   PubMed Web of Science ®Google Scholar
• Peaceman AM, Silver RK, Mac Gregor SM, Socol ML. Interlaboratory variation in antiphospholipid antibody test-ing. Am J Obst Gynecol 1992;166:1780–7.
   PubMed Web of Science ®Google Scholar
• Reber G, Arvieux J, Comby E, Degenne D, de Moerloose P, Sanmarco M, et al. Multicenter evaluation of nine kits for the quantitation of anticardiolipin antibodies. Thromb Haemost 1995;52:444 —52.
   Google Scholar
• Erickson EM, Najmey SS, Keil LB, El-Kady HS, De Bari VA. Reference calibrators for IgG antibodies to 132-glycoprotein I: Preparation, properties and availability to investigators. Clin Chem 1996;42: 1116–7.
   Google Scholar
• Alarcon-Segovia D, Mestanza M, Cabiedes Cabral A. The antiphospholipid/cofactor syndromes. A variant in patients with systemic lupus erithematosus with antibodies to I32GPI but no antibodies detectable in standard antiphospholipid assays. J Rheumatol 1997;24: 1545–51.
   Google Scholar